AI Article Synopsis
- No cure exists for recurrent and metastatic cervical cancer, and current chemotherapy options are limited and often ineffective.
- Immune checkpoint inhibitors like pembrolizumab have demonstrated strong responses in some cancer patients, but their effectiveness varies among individuals.
- A case study is presented where a patient with advanced cervical cancer, who had tried all other treatments, responded remarkably well to pembrolizumab, highlighting its potential in tough cases.
Article Abstract
No definitive cure is known for recurrent, persistent or metastatic cervical carcinoma. Chemotherapy remains the standard of care, although available options are scarce and do not provide satisfactory results. Immune checkpoint inhibitors have shown a strong and prolonged response in several types of cancer, although only in a subset of patients. Defining the profile of the patients likely to benefit from such treatment is a subject of active research. Here, we present a case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatment options and showed a striking response to the immune checkpoint inhibitor pembrolizumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2016-0119 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Through-tunnel reconstruction with Ligament Augmentation and Reconstruction System (LARS) for managing post-arthroplasty patellofemoral instability.
BMC Musculoskelet Disord
January 2025
Division of Orthopedic Surgery, Changhua Christian Hospital, Changhua, Taiwan.
Background: Despite advancements in prosthetic designs and surgical techniques, patellar dislocation remains a rare but significant complication following total knee arthroplasty, with an incidence ranging between 0.15% and 0.5%.
View Article and Find Full Text PDFTreatment advances across the cervical cancer spectrum.
Nat Rev Clin Oncol
January 2025
Department of Obstetrics and Gynecology, University of California, Irvine, Irvine, CA, USA.
Cervical cancer is preventable with screening and vaccination approaches; however, access to these preventative measures is limited both nationally and globally and thus many women will still develop cervical cancer. Novel treatments and practice-changing research have improved cervical cancer outcomes over the past few decades. In this Review, we discuss clinical trials that have refined or redefined the treatment of cervical cancers across the early stage, locally advanced, persistent, recurrent and/or metastatic disease settings.
View Article and Find Full Text PDFLAPTM5 Confers the Resistance to Venetoclax via Promoting the Autophagosome-Lysosome Fusion in Multiple Myeloma.
J Cell Mol Med
January 2025
School of Life Sciences, Anhui Medical University, Hefei, China.
Multiple myeloma (MM) is a haematological lymphoid malignancy marked by significant morbidity due to severe complications. Despite advances in targeted therapies, including proteasome inhibitors and the BCL-2 inhibitor venetoclax, drug resistance frequently occurs, with the underlying mechanisms poorly understood. This study investigates the role of lysosome-associated protein transmembrane 5 (LAPTM5) in conferring resistance to venetoclax in relapsed MM.
View Article and Find Full Text PDFPhase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma.
Clin Lung Cancer
December 2024
Georgetown University, Washington, DC. Electronic address:
Background: Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare thoracic tumors of the anterior mediastinum. For those with advanced disease, platinum-based chemotherapy is used as first-line treatment. However, there is no standard regimen established for TET at progression after initial therapy, and treatment options for advanced/recurrent TETs are limited.
View Article and Find Full Text PDFPatellar Instability After Total Knee Arthroplasty.
J Knee Surg
January 2025
Lenox Hill Hospital Department of Orthopedic Surgery, Northwell Health, New York, United States.
Patellar instability following total knee arthroplasty (TKA) is a rare, yet serious complication, potentially requiring revision surgery or resulting in chronic dysfunction. When encountered, it is paramount to understand the etiologies, diagnostic approaches, treatment options, and outcomes of the selected treatment. The most common cause of patella instability is improper positioning of components, leading to lateral maltracking of the patella.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!